for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
The Medical Letter
   [5 followers]  Follow    
   Full-text available via subscription Subscription journal
     ISSN (Print) 0025-732X - ISSN (Online) 1523-2859
     Published by The Medical Letter, Inc Homepage  [1 journal]   [SJR: 0.161]   [H-I: 15]
  • In Brief: Heptavalent Botulism Antitoxin - The Medical Letter
    • Authors: admin
      Abstract: May 26, 2014 - The FDA has approved the use of an equine heptavalent botulism antitoxin (BAT, Cangene Corporation). The new antitoxin includes antibodies against all 7 botulinum neurotoxin types (A-G). A human-derived antitoxin (BabyBIG) has been available for years for infant botulism. The heptavalent product is now the preferred antitoxin for adult botulism. It is a solution of immunoglobulin fragments obtained from equine plasma that has gone through several steps of purifi cation and viral inactivation. (The use of immunoglobulin fragments reduces side effects compared to intact immunoglobulin.) BAT is available from the CDC...
  • Eslicarbazepine Acetate (Aptiom) for Epilepsy - The Medical Letter
    • Authors: admin
      Abstract: May 26, 2014 - Eslicarbazepine acetate (Aptiom – Sunovion) has been approved by the FDA for adjunctive treatment of partial-onset seizures in adults. New drugs for epilepsy are often approved by the FDA initially only as adjunctive treatment for partial seizures. Eslicarbazepine acetate is a prodrug of eslicarbazepine, which is the S-isomer of the active metabolite of oxcarbazepine. Oxcarbazepine itself is similar to carbamazepine. Both oxcarbazepine and carbamazepine are available generically.
  • Sorafenib (Nexavar) for Thyroid Cancer - The Medical Letter
    • Authors: admin
      Abstract: May 26, 2014 - The FDA has approved the use of the oral multikinase inhibitor sorafenib (Nexavar – Bayer) for treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer (papillary or follicular) refractory to radioactive iodine treatment. Sorafenib was approved earlier for treatment of advanced renal cell and unresectable hepatocellular cancer.
  • Adult Immunization - Treatment Guidelines
    • Authors: admin
      Abstract: June 1, 2014 - Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately.
  • Apremilast (Otezla) for Psoriatic Arthritis - The Medical Letter
    • Authors: admin
      Abstract: May 26, 2014 - Apremilast (Otezla – Celgene), an oral phosphodiesterase type-4 (PDE4) inhibitor, has been approved by the FDA for treatment of active psoriatic arthritis in adults. It is the fi rst PDE4 inhibitor to be approved for this indication.
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014